Summary by Moomoo AI
On June 25, 2024, Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced significant progress in its Phase 2 clinical trial for stenoparib, a treatment for advanced recurrent ovarian cancer. The trial has shown that multiple patients have been on treatment for over 30 weeks, demonstrating the drug's extended clinical benefit. This follows an earlier announcement in May 2024, where stenoparib was reported to have significant tumor shrinkage and long-term disease stability in heavily pre-treated patients. The company has decided to halt patient enrollment to focus on a follow-on trial aimed at accelerating stenoparib's path to regulatory approval. The trial's Principal Investigator, Kathleen N. Moore, MD, highlighted the need for continued development of next-generation PARP inhibitors like stenoparib...Show More
